07:00 , May 18, 2015 |  BC Week In Review  |  Company News

Actavis, TPG Capital deal

Actavis completed the divestiture of its Aptalis Pharmaceutical Technologies subsidiary to private investment firm TPG for an undisclosed sum. Aptalis said that its new name is Adare Pharmaceuticals (see BioCentury, Feb. 16). Actavis Group, Zug,...
08:00 , Feb 16, 2015 |  BC Week In Review  |  Company News

Actavis, TPG Capital deal

Actavis will divest its Aptalis Pharmaceutical Technologies outsourcing and R&D business to private investment firm TPG for an undisclosed sum. The deal is expected to close by mid-year. Actavis said the move will allow it...
08:00 , Nov 3, 2014 |  BC Week In Review  |  Clinical News

Dalbavancin: SPA received

Durata said it received an SPA from FDA for a Phase III trial to compare a single dose of 1,500 mg IV Dalvance plus a single dose of IV azithromycin vs. linezolid plus azithromycin in...
07:00 , Oct 13, 2014 |  BC Week In Review  |  Company News

Durata Therapeutics, Actavis deal

Actavis will acquire Durata for $23 per share in cash up front, or $675 million, plus up to $146.5 million in regulatory and commercial milestones in the form of a contingent value right (CVR) worth...
07:00 , Apr 7, 2014 |  BC Week In Review  |  Company News

HRA Pharma, Afaxys Inc. sales and marketing update

The Afaxys Pharmaceuticals division of Afaxys relaunched emergency contraceptive ella ulipristal acetate in the U.S. Afaxys has exclusive U.S. commercialization rights to the product from HRA Pharma. Afaxys declined to disclose details, and...
07:00 , Jul 1, 2013 |  BC Week In Review  |  Clinical News

Fibristal ulipristal acetate regulatory update

Actavis said Health Canada approved Fibristal ulipristal acetate to treat moderate to severe signs and symptoms of uterine fibroids in adult women of reproductive age who are eligible for surgery. The company plans to launch...
08:00 , Jan 21, 2013 |  BC Week In Review  |  Clinical News

MoxDuo IR morphine/oxycodone regulatory update

QRxPharma said it will resubmit an NDA this quarter for MoxDuo IR (12 mg morphine/8 mg oxycodone) to manage acute pain following clarification with FDA on the necessary steps for approval. The company expects a...
08:00 , Dec 17, 2012 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 12/14 cls Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) Roth Capital Partners Scott Henry New Buy...
08:00 , Nov 12, 2012 |  BC Week In Review  |  Company News

Actavis, Watson deal

Watson completed its acquisition of fellow generics company Actavis for €4.3 billion ($5.5 billion) in cash. Watson said it will change its name to Actavis and adopt a new trading symbol on the NYSE, effective...
07:00 , Oct 29, 2012 |  BioCentury  |  Finance

NextWave's option arithmetic

NextWave Pharmaceuticals Inc.'s investors are in line for at least a 2.5X return on the $105 million they have put into the CNS company after Pfizer Inc. (NYSE:PFE) exercised an option to acquire it last...